Study drug combo for advanced lung cancer after PD-1 treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and sign consent (including permission for future research).
- Have advanced non-small cell lung cancer confirmed by biopsy/pathology, and measurable tumors on scans.
- Have had prior treatment with chemo (platinum-based) and/or immunotherapy, and then your cancer must have progressed on an anti–PD-1/PD-L1 medicine (like pembrolizumab) after at least 2 doses.
- Have had at least one tumor tissue sample (archived sample or a new biopsy) for study testing.
- Have basic blood and organ test results that meet specific cutoffs (including neutrophils, platelets, hemoglobin, kidney, liver, and blood clotting), and you should be able to do daily activities (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
This trial tests a combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced lung cancer that stopped responding to a PD-1 inhibitor. The goal is to see if this new triple therapy can help shrink tumors or slow down the cancer.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.